4‑Methoxydalbergione inhibits the tumorigenesis and metastasis of lung cancer through promoting ferroptosis via the DNMT1/system Xc‑/GPX4 pathway

Fan,Jun; Lin,Haoran; Luo,Jinhua; Chen,Liang

doi:10.3892/mmr.2024.13384

4‑Methoxydalbergione inhibits the tumorigenesis and metastasis of lung cancer through promoting ferroptosis via the DNMT1/system Xc‑/GPX4 pathway

Authors:
- Jun Fan
- Haoran Lin
- Jinhua Luo
- Liang Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China
Published online on: November 5, 2024 https://doi.org/10.3892/mmr.2024.13384
Article Number: 19
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is responsible for the highest number of tumor‑related deaths worldwide. A flavonoid extracted from the heartwood of Dalbergia sissoo Roxb., 4‑methoxydalbergione (4‑MD), exhibits potent anticancer activity in multiple malignancies; however, the potential anticancer activity of 4‑MD in lung cancer has not yet been elucidated. In the present study, A549 cells were treated with increasing concentrations of 4‑MD, and cell viability was assessed using a Cell Counting Kit‑8 assay. In addition, colony formation, 5‑ethynyl‑2'‑deoxyuridine, wound healing and Transwell assays were conducted to evaluate cell proliferation, migration and invasion, respectively. Cell morphology was observed using transmission electron microscopy, and ferroptosis was determined using thiobarbituric acid reactive substance, lipid reactive oxygen species (ROS) and iron assays. Moreover, molecular docking was used to verify the potential interaction between 4‑MD and DNA methyltransferase 1 (DNMT1). Tumor‑bearing mice were established and treated with 10 or 30 mg/kg 4‑MD, and tumor volume and weight were recorded. Immunohistochemistry and Prussian blue staining were conducted to examine Ki‑67 expression and iron deposition in tumor tissues, and protein expression was further explored using western blot analysis. The results of the present study revealed that 4‑MD significantly inhibited cell proliferation, migration, invasion and epithelial‑mesenchymal transition in a concentration‑dependent manner. Notably, 4‑MD induced ferroptosis via increased lipid peroxidation, lipid ROS and Fe2+ levels. In addition, it was revealed that 4‑MD can directly bind to DNMT1 to inhibit expression, and inhibit solute carrier family 7 member 11 (SLC7A11; also known as cystine‑glutamate antiporter) and glutathione peroxidase 4 expression. Following DNMT1 overexpression, the observed antitumor activity and ferroptosis‑promoting effects of 4‑MD were partially reversed. Furthermore, 4‑MD significantly inhibited tumor growth in vivo, and reduced tumor volume and weight. In addition, Ki‑67 expression was reduced while iron deposition was increased in the tumor tissues of mice following treatment with 4‑MD. In conclusion, 4‑MD may exhibit anticancer activity through the promotion of DNMT1‑mediated cell ferroptosis. Thus, 4‑MD may have potential as a novel therapeutic agent in the treatment of lung cancer.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, et al: Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 11:22852020. View Article : Google Scholar : PubMed/NCBI
4	Lambert AW, Pattabiraman DR and Weinberg RA: Emerging biological principles of metastasis. Cell. 168:670–691. 2017. View Article : Google Scholar : PubMed/NCBI
5	Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L, Zhao M, Liu Q, Cheng Z, Zou J, et al: Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine. Chin Med. 14:482019. View Article : Google Scholar : PubMed/NCBI
6	Chan SC, Chang YS, Wang JP, Chen SC and Kuo SC: Three new flavonoids and antiallergic, anti-inflammatory constituents from the heartwood of Dalbergia odorifera. Planta Med. 64:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
7	Kim DC, Lee DS, Ko W, Kim KW, Kim HJ, Yoon CS, Oh H and Kim YC: Heme Oxygenase-1-Inducing Activity of 4-Methoxydalbergione and 4′-Hydroxy-4-methoxydalbergione from Dalbergia odorifera and Their Anti-inflammatory and Cytoprotective Effects in Murine Hippocampal and BV2 microglial cell line and primary rat microglial cells. Neurotox Res. 33:337–352. 2018. View Article : Google Scholar : PubMed/NCBI
8	Du H, Tao T, Xu S, Xu C, Li S, Su Q, Yan J, Liu B and Li R: 4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway. Front Mol Biosci. 8:7896582022. View Article : Google Scholar : PubMed/NCBI
9	Zeng L, Qin Y, Lu X, Fang X, Huang J, Yu C and Feng ZB: 4-Methoxydalbergione Elicits Anticancer Effects by Upregulation of GADD45G in Human Liver Cancer Cells. J Healthc Eng. 2023:67108802023. View Article : Google Scholar : PubMed/NCBI
10	Li M, Xiao Y, Liu P, Wei L, Zhang T, Xiang Z, Liu X, Zhang K, Zhong Q and Chen F: 4-Methoxydalbergione inhibits esophageal carcinoma cell proliferation and migration by inactivating NF-ĸB. Oncol Rep. 49:422023. View Article : Google Scholar : PubMed/NCBI
11	Li R, Xu CQ, Shen JX, Ren QY, Chen DL, Lin MJ, Huang RN, Li CH, Zhong RT, Luo ZH, et al: 4-Methoxydalbergione is a potent inhibitor of human astroglioma U87 cells in vitro and in vivo. Acta Pharmacol Sin. 42:1507–1515. 2021. View Article : Google Scholar : PubMed/NCBI
12	Park KR, Yun HM, Quang TH, Oh H, Lee DS, Auh QS and Kim EC: 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway. Oncotarget. 7:6960–6971. 2016. View Article : Google Scholar : PubMed/NCBI
13	Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA and Lei P: Ferroptosis: Mechanisms and links with diseases. Signal Transduct Target Ther. 6:492021. View Article : Google Scholar : PubMed/NCBI
14	Hassannia B, Vandenabeele P and Vanden Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell. 35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
15	Liang C, Zhang X, Yang M and Dong X: Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al: The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18:e30004102020. View Article : Google Scholar : PubMed/NCBI
18	Pritt SL and Smith TM: Institutional animal care and use committee postapproval monitoring programs: A proposed comprehensive classification scheme. J Am Assoc Lab Anim Sci. 59:127–131. 2020. View Article : Google Scholar : PubMed/NCBI
19	Zhang X, Wang R, Piotrowski M, Zhang H and Leach KL: Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 29:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang J, Gao M, Niu Y and Sun J: From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer. Biochem Biophys Res Commun. 603:75–81. 2022. View Article : Google Scholar : PubMed/NCBI
21	Zeng J, Li X, Liang L, Duan H, Xie S and Wang C: Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion. J Cancer Res Clin Oncol. 148:137–153. 2022. View Article : Google Scholar : PubMed/NCBI
22	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
23	Muthusamy B, Patil PD and Pennell NA: Perioperative systemic therapy for resectable non-small cell lung cancer. J Natl Compr Canc Netw. 20:953–961. 2022. View Article : Google Scholar : PubMed/NCBI
24	Xie S, Wu Z, Qi Y, Wu B and Zhu X: The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother. 138:1114502021. View Article : Google Scholar : PubMed/NCBI
25	Bakir B, Chiarella AM, Pitarresi JR and Rustgi AK: EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 30:764–776. 2020. View Article : Google Scholar : PubMed/NCBI
26	Chanvorachote P, Petsri K and Thongsom S: Epithelial to mesenchymal transition in lung cancer: Potential EMT-Targeting natural product-derived compounds. Anticancer Res. 42:4237–4246. 2022. View Article : Google Scholar : PubMed/NCBI
27	Menju T and Date H: Lung cancer and epithelial-mesenchymal transition. Gen Thorac Cardiovasc Surg. 69:781–789. 2021. View Article : Google Scholar : PubMed/NCBI
28	Ye J, Zhang R, Wu F, Zhai L, Wang K, Xiao M, Xie T and Sui X: Non-apoptotic cell death in malignant tumor cells and natural compounds. Cancer Lett. 420:210–227. 2018. View Article : Google Scholar : PubMed/NCBI
29	Xu R, Wu J, Luo Y, Wang Y, Tian J, Teng W, Zhang B, Fang Z and Li Y: Sanguinarine represses the growth and metastasis of non-small cell lung cancer by facilitating ferroptosis. Curr Pharm Des. 28:760–768. 2022. View Article : Google Scholar : PubMed/NCBI
30	Qian X, Zhu L, Xu M, Liu H, Yu X, Shao Q and Qin J: Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation. Chem Biol Interact. 382:1105882023. View Article : Google Scholar : PubMed/NCBI
31	Yang WS and Stockwell BR: Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 26:165–176. 2016. View Article : Google Scholar : PubMed/NCBI
32	Yao ZJ, Dong J, Che YJ, Zhu MF, Wen M, Wang NN, Wang S, Lu AP and Cao DS: TargetNet: A web service for predicting potential drug-target interaction profiling via multi-target SAR models. J Comput Aided Mol Des. 30:413–424. 2016. View Article : Google Scholar : PubMed/NCBI
33	Wu XY, Chen HC, Li WW, Yan JD and Lv RY: DNMT1 promotes cell proliferation via methylating hMLH1 and hMSH2 promoters in EGFR-mutated non-small cell lung cancer. J Biochem. 168:151–157. 2020. View Article : Google Scholar : PubMed/NCBI
34	Ma F, Lei YY, Ding MG, Luo LH, Xie YC and Liu XL: LncRNA NEAT1 Interacted With DNMT1 to regulate malignant phenotype of cancer cell and cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer. Front Genet. 11:2502020. View Article : Google Scholar : PubMed/NCBI
35	Zou P, Chen Z, He Q and Zhuo Y: Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis. Prostate. 84:64–73. 2024. View Article : Google Scholar : PubMed/NCBI